1. Home
  2. NRIX vs SHO Comparison

NRIX vs SHO Comparison

Compare NRIX & SHO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nurix Therapeutics Inc.

NRIX

Nurix Therapeutics Inc.

N/A

Current Price

$15.88

Market Cap

1.7B

Sector

Health Care

ML Signal

N/A

SHO

Sunstone Hotel Investors Inc. Sunstone Hotel Investors Inc.

N/A

Current Price

$9.26

Market Cap

1.8B

ML Signal

N/A

Company Overview

Basic Information
Metric
NRIX
SHO
Founded
2009
1995
Country
United States
United States
Employees
N/A
36
Industry
Biotechnology: Pharmaceutical Preparations
Hotels/Resorts
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.8B
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
NRIX
SHO
Price
$15.88
$9.26
Analyst Decision
Strong Buy
Hold
Analyst Count
13
8
Target Price
$29.46
$9.19
AVG Volume (30 Days)
844.9K
1.9M
Earning Date
05-01-2026
01-01-0001
Dividend Yield
N/A
3.89%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$76,987,000.00
N/A
Revenue This Year
N/A
$5.85
Revenue Next Year
$29.30
$3.56
P/E Ratio
N/A
$966.33
Revenue Growth
99.31
N/A
52 Week Low
$8.18
$7.45
52 Week High
$22.50
$10.67

Technical Indicators

Market Signals
Indicator
NRIX
SHO
Relative Strength Index (RSI) 42.26 52.99
Support Level $15.62 $8.66
Resistance Level $19.98 $9.35
Average True Range (ATR) 0.78 0.23
MACD -0.03 0.02
Stochastic Oscillator 36.46 65.38

Price Performance

Historical Comparison
NRIX
SHO

About NRIX Nurix Therapeutics Inc.

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

About SHO Sunstone Hotel Investors Inc. Sunstone Hotel Investors Inc.

Sunstone Hotel Investors Inc is a real estate investment trust that acquires, owns, manages, and renovates the full-service hotel and select-service hotel properties across various states in the United States. Its firm's portfolio consists upper upscale and luxury hotels located in convention, resort destination and urban markets. Its majority of the hotels operate under a brand owned by Marriott, Hilton, Hyatt, Four Seasons or Montage. It operates geographically in Califiornia which generates the majority of its revenue; Florida; and Hawaii. The company's sole source of income is hotel revenue from its hotel ownership segment.

Share on Social Networks: